コンテンツへスキップ
Merck
  • An in vivo antilymphatic screen in zebrafish identifies novel inhibitors of mammalian lymphangiogenesis and lymphatic-mediated metastasis.

An in vivo antilymphatic screen in zebrafish identifies novel inhibitors of mammalian lymphangiogenesis and lymphatic-mediated metastasis.

Molecular cancer therapeutics (2014-07-24)
Jonathan W Astin, Stephen M F Jamieson, Tiffany C Y Eng, Maria V Flores, June P Misa, Annie Chien, Kathryn E Crosier, Philip S Crosier
要旨

The growth of new lymphatic vessels (lymphangiogenesis) in tumors is an integral step in the metastatic spread of tumor cells, first to the sentinel lymph nodes that surround the tumor and then elsewhere in the body. Currently, no selective agents designed to prevent lymphatic vessel growth have been approved for clinical use, and there is an important potential clinical niche for antilymphangiogenic agents. Using a zebrafish phenotype-based chemical screen, we have identified drug compounds, previously approved for human use, that have antilymphatic activity. These include kaempferol, a natural product found in plants; leflunomide, an inhibitor of pyrimidine biosynthesis; and cinnarizine and flunarizine, members of the type IV class of calcium channel antagonists. Antilymphatic activity was confirmed in a murine in vivo lymphangiogenesis Matrigel plug assay, in which kaempferol, leflunomide, and flunarizine prevented lymphatic growth. We show that kaempferol is a novel inhibitor of VEGFR2/3 kinase activity and is able to reduce the density of tumor-associated lymphatic vessels as well as the incidence of lymph node metastases in a metastatic breast cancer xenograft model. However, in this model, kaempferol administration was also associated with tumor deposits in the pancreas and diaphragm, and flunarizine was found to be tumorigenic. Although this screen revealed that zebrafish is a viable platform for the identification and development of mammalian antilymphatic compounds, it also highlights the need for focused secondary screens to ensure appropriate efficacy of hits in a tumor context.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
エチルアルコール(純粋), for molecular biology
Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
エタノール, JIS special grade, ≥99.5%
Sigma-Aldrich
L-リシン 一塩酸塩, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
エタノール, SAJ first grade, ≥99.5%
Sigma-Aldrich
ラパマイシン, Ready Made Solution, 2.5 mg/mL in DMSO (2.74 mM), from Streptomyces hygroscopicus
Sigma-Aldrich
エチルアルコール(純粋), 190 proof, ACS spectrophotometric grade, 95.0%
Sigma-Aldrich
エタノール, purum, fine spirit, denaturated with 4.8% methanol, F25 METHYL1, ~96% (based on denaturant-free substance)
Supelco
エタノール 溶液, certified reference material, 2000 μg/mL in methanol
Sigma-Aldrich
エタノール, puriss. p.a., absolute, ≥99.8% (GC)
Supelco
エタノール標準品10% (v/v), 10 % (v/v) in H2O, analytical standard
USP
エタノール, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
エタノール, ≥99.5%, suitable for HPLC
Sigma-Aldrich
エタノール, JIS special grade, 94.8-95.8%
Sigma-Aldrich
シンナリジン, powder
Sigma-Aldrich
エタノール, ≥99.5%
Sigma-Aldrich
レフルノミド, Immunosuppressant
Sigma-Aldrich
フルナリジン 二塩酸塩, ≥98% (TLC)
Sigma-Aldrich
L-リシン 一塩酸塩, reagent grade, ≥98% (HPLC)
Sigma-Aldrich
エタノール, ≥99.5%, suitable for absorption spectrum analysis
Sigma-Aldrich
Ethanol Fixative 80% v/v, suitable for fixing solution (blood films)
Sigma-Aldrich
エタノール, JIS first grade, 94.8-95.8%
USP
レフルノミド, United States Pharmacopeia (USP) Reference Standard
Supelco
L-リシン 一塩酸塩, Pharmaceutical Secondary Standard; Certified Reference Material
リシン 塩酸塩, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
エタノール, ≥99.5%, SAJ super special grade
Sigma-Aldrich
L-リシン 一塩酸塩, BioUltra, ≥99.5% (AT)
Supelco
ラパマイシン, VETRANAL®, analytical standard
Isoflurane, European Pharmacopoeia (EP) Reference Standard